All-trans retinoic acid induces nerve regeneration and increases serum and nerve contents of neural growth factor in experimental diabetic neuropathy.
Local diminution of the neural growth factor (NGF) contributes to the apparition of diabetic neuropathy. All-trans retinoic acid (RA) increases the expression of neural growth factor and its receptor participating in translation pathways. This study evaluates RA as a treatment of diabetic neuropathy: 120 mice were assigned randomly to 4 groups. Group A (n = 30) was taken as control; group B (n = 30) received 50 mg/kg intraperitoneal streptozotocin (STZ); group C (n = 30) received STZ, and after diabetic neuropathy developed, they were treated with subcutaneous RA 20 mg/kg daily during 60 days; and group D (n = 30) only received RA. Plasma glucose, thermosensitive tests, serum, and the nerve contents of NGF were measured in all animals. Evaluation by electron microscopy was performed in search of morphologic changes secondary to neuropathy and nerve regeneration. Diabetic mice had an increased threshold to pain. Treatment with RA in diabetic mice reverted changes in sensitivity as compared with diabetic mice that received placebo (P < 0.001). No differences in pain threshold among controls, RA, and diabetes mellitus (DM) + RA groups were found. Glucose levels were not affected by the treatment with RA. NGF diminished significantly in the sciatic nerve in diabetic mice as compared with controls and with the RA group. Animals with DM + RA had a significant increase of NGF in nerves as compared with the other groups. RA also regressed the ultrastructural changes induced by diabetes that showed increased neural regeneration. RA can revert functional and ultrastructural changes and induce neural regeneration after the establishment of diabetic neuropathy, possibly because of the increased of NGF concentrations in nerve terminals.
Hernández-Pedro
Norma
N
Neuroimmunology Unit and the Experimental Neuropathology Department, Instituto Nacional de Neurología y Neurocirugía, México.
Ordóñez
Graciela
G
Ortiz-Plata
Alma
A
Palencia-Hernández
Guadalupe
G
García-Ulloa
Ana Cristina
AC
Flores-Estrada
Diana
D
Sotelo
Julio
J
Arrieta
Oscar
O
D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000378:metabolism* / Q000473:pathology; D003929:Diabetic Neuropathies / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D004353:Drug Evaluation, Preclinical; D008297:Male; D051379:Mice; D020932:Nerve Growth Factor / Q000097:blood / Q000378:metabolism*; D009416:Nerve Regeneration / Q000187:drug effects*; D011897:Random Allocation; D012584:Sciatic Nerve / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D014212:Tretinoin / Q000494:pharmacology* / Q000627:therapeutic use
D001786:Blood Glucose; D014212:Tretinoin; D020932:Nerve Growth Factor